

---

November 13, 2024

The Honorable Charles Schumer  
Majority Leader  
US Senate  
S-221 Capitol Building  
Washington, DC 20510

The Honorable Mitch McConnell  
Minority Leader  
US Senate  
S-230 Capitol Building  
Washington, DC 20510

The Honorable Mike Johnson  
Speaker of the House  
US House of Representatives  
H-232 Capitol Building  
Washington, DC 20515

The Honorable Hakeem Jeffries  
Minority Leader  
US House of Representatives  
H-204 Capitol Building  
Washington, DC 20515

---

Dear Leaders Schumer and McConnell, Speaker Johnson, and Leader Jeffries,

On behalf of the undersigned organizations, we write to urge you to include a comprehensive reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) in a legislative package before the end of the 118<sup>th</sup> Congressional Session.

The Senate and House health committees have each passed reauthorization bills that make critical improvements to our nation's health security infrastructure—these threats—whether they emerge from advances in biotechnology and art

naturally occurring outbreaks, major storms, deliberate attacks, or accidents—require an agile, authorized, responsive government infrastructure.

The PAHPA framework, which was originally authorized 17 years ago, expired on September 30, 2023, requiring stopgap, temporary extensions in prior continuing resolutions. However, we urge you to pass a comprehensive PAHPA reauthorization package, one that includes key new provisions that strengthen US preparedness and response capabilities, before the end of the year.

The last three PAHPA reauthorization packages shared major recurring themes: they all adjusted to the changing threat landscape, focused on challenges identified since the prior bill, and strengthened our nation's health security with each reauthorization. A new reauthorization bill would continue to do that by strengthening existing programs and continuing to adapt and improve America's health security infrastructure for new and future challenges.

Failing to reauthorize PAHPA now would have serious effects on our country's economic wellbeing, national security, and health given the rapidly changing threat landscape. For example, Congress would leave critical preparedness programs—like the Strategic National Stockpile, medical supply chain resilience, and hospital preparedness programs—without clear direction and oversight.

---

We are hopeful that PAHPA will remain a strong bipartisan legislative framework, as it has always been. We stand ready to assist you however we can to help get this important law reauthorized this year.

Thank you for your attention to this critical matter; please contact Joel Straus at [joel.straus@jhu.edu](mailto:joel.straus@jhu.edu) with any questions.

Sincerely (in alphabetical order),

**1Day Sooner**

**Acadian Companies**

**Adjuvant Capital, LP**

**AdvaMed**

**Aequor Inc.**

**American Academy of Pediatrics**

**American Ambulance Association**

**American Clinical Laboratory Association**

**American College of Emergency Physicians**

**American College of Physicians**

**American College of Surgeons**

**American Lung Association**

**American Medical Manufacturers Association  
(AMMA)**

**American Public Health Association**

**American Society for Microbiology**

**Antheia, Inc.**

**Arizona Bioindustry Association, Inc. (AZBio)**

**Association of American Medical Colleges**

**Association of Maternal & Child Health  
Programs**

**Association of Public Health Laboratories**

**Asthma and Allergy Foundation of America**

**ATCC**

**Atea Pharmaceuticals, Inc.**

**Bavarian Nordic**

**Big Cities Health Coalition**

**BIO**

**Biocom California**

**BioCT**

**BioForward Wisconsin**

**BioNJ**

**BioUtah**

**BluZoneBio LLC**

**Bugworks**

**California Life Sciences**

**Cencora (formerly AmerisourceBergen)**

**Civitas Networks for Health**

**Codagenix**

**Colorado BioScience Association**

**Council of State and Territorial Epidemiologists**

**Council of State Bioscience Associations**

**Dentec Safety Specialists**

**Elusys Therapeutics, Inc.**

**Emergent BioSolutions**

**Federation of American Hospitals**

---

<b>Hamilton Grace LLC</b>	<b>New Mexico Biotechnology &amp; Biomedical Association</b>
<b>Harvard Kennedy School, Belfer Center for Science and International Affairs</b>	<b>New Orleans BioInnovation Center</b>
<b>Health Industry Distributors Association</b>	<b>NewYorkBIO</b>
<b>Health Supply US</b>	<b>Ohio Life Sciences</b>
<b>Healthcare Distribution Alliance</b>	<b>Oregon Bioscience Association</b>
<b>Healthcare Information and Management Systems Society (HIMSS)</b>	<b>Premier Inc.</b>
<b>Helix, Inc.</b>	<b>Public Health Accreditation Board</b>
<b>High Alert Institute, Inc.</b>	<b>READDI, Inc.</b>
<b>HIV Medicine Association</b>	<b>Recce Pharmaceuticals Ltd</b>
<b>IAVI</b>	<b>Research!America</b>
<b>Illinois Biotechnology Innovation Organization, iBIO</b>	<b>Roche Diagnostics</b>
<b>Indiana Life Sciences Association</b>	<b>SAB Biotherapeutics, Inc.</b>
<b>Infectious Diseases Society of America</b>	<b>Sanofi</b>
<b>Institute for Progress</b>	<b>Scbio</b>
<b>Johns Hopkins Center for Health Security</b>	<b>Scorpius Biomanufacturing</b>
<b>Life Science Tennessee</b>	<b>Shionogi Inc.</b>
<b>Life Sciences Pennsylvania</b>	<b>SIGA Technologies, Inc.</b>
<b>Maryland Tech Council</b>	<b>SoCalBio</b>
<b>Mass General Brigham</b>	<b>Society for Public Health Education</b>
<b>Massachusetts Biotechnology Council (MassBio)</b>	<b>South Dakota Biotech Association</b>
<b>Maxter Healthcare Inc</b>	<b>SPOC Proteomics, Inc.</b>
<b>Medical Alley</b>	<b>Texas Healthcare &amp; Bioscience Institute</b>
<b>Medical Countermeasures Coalition</b>	<b>Tonix Pharmaceuticals, Inc</b>
<b>Michigan Biosciences Industry Association (MichBio)</b>	<b>Trinity Health</b>
<b>Missouri Biotechnology Association</b>	<b>TrippBio, Inc.</b>
<b>Montana BioScience Alliance</b>	<b>Trust for America's Health</b>
<b>Mount Sinai Health System</b>	<b>United Safety Technology Inc.</b>
<b>NC Life Sciences Organization</b>	<b>University of Nebraska System</b>
<b>Neuroene Therapeutics</b>	<b>Valneva USA</b>
	<b>Vaxxas Inc</b>
	<b>VIDA</b>